FindTrial
Sign In

Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-513907-15-01
Acronym
NL79765.029.21
Enrollment
140
Registered
2024-10-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

Inventory of Depressive Symptomatology (IDS, 30-item self-report) total score during 12 week follow-up

Detailed description

response (50% reduction in IDS score), remission (diagnostic interview), Adverse side effects, Symptom profiles (atypical, energy-related symptoms IDS), Fatigue (CIS), Food craving (GFCQ-T), Sleep and sleep duration (ESS, sleep duration from PSQI), Anxiety symptoms (GAD7), Functioning (WHO-DAS), Pain (numeric rating scale), Therapy compliance, Change in blood levels of CRP, IL-6, TNF-α, cholesterol, triglycerides,glucose

Interventions

DRUGPlacebo
DRUGCelecoxib Teva 200 mg
DRUGcapsules
DRUGhard

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Inventory of Depressive Symptomatology (IDS, 30-item self-report) total score during 12 week follow-up—

Secondary

MeasureTime frame
response (50% reduction in IDS score), remission (diagnostic interview), Adverse side effects, Symptom profiles (atypical, energy-related symptoms IDS), Fatigue (CIS), Food craving (GFCQ-T), Sleep and sleep duration (ESS, sleep duration from PSQI), Anxiety symptoms (GAD7), Functioning (WHO-DAS), Pain (numeric rating scale), Therapy compliance, Change in blood levels of CRP, IL-6, TNF-α, cholesterol, triglycerides,glucose—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026